Management protocol for abacavir-related hypersensitivity reaction

OBJECTIVE: To develop an abacavir hypersensitivity reaction management protocol for the University of Oklahoma Health Sciences Center. DATA SYNTHESIS: Conference abstracts, published literature, and manufacturer-provided materials were reviewed to define the syndrome and manifestations and to recommend steps to take when a patient develops abacavir-related reactions. RESULTS: Initial education, formalized contact and response mechanism, and intervention levels were incorporated into a protocol for clinicians. CONCLUSIONS: Abacavir, a newly approved agent for the treatment of HIV, has been associated with a fatal hypersensitivity reaction. Our protocol provides a mechanism to minimize progression of abacavir hypersensitivity reaction by providing a formalized management procedure.

This article has been cited by other articles:

				K. E. Estes, K. H. Busse, and S. R. Penzak Pharmacogenetic Considerations in the Management of HIV Infection Journal of Pharmacy Practice, June 1, 2007; 20(3): 234 - 245. [Abstract] [PDF]

				H. Peyriere, V. Guillemin, A. Lotthe, V. Baillat, J. Fabre, C. Favier, N. Atoui, S. Hansel, D. Hillaire-Buys, and J. Reynes Reasons for Early Abacavir Discontinuation in HIV-Infected Patients Ann. Pharmacother., October 1, 2003; 37(10): 1392 - 1397. [Abstract] [Full Text] [PDF]